Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Assiut University Trauma HospitalAsyut, EgyptContact: Esraa M.H IbrahimNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT07566520
- Record updated
- 5 May 2026
- Original description
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.Read full original descriptionShow less
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.
Inclusion: Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria; Patients who are willing to participate and provide informed written consent.Exclusion Criteria:; Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting; Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement; Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)); Severe Comorbidities: end-stage renal or hepatic disease, advanced malignancy or cachexia; Severe neurological disorders (e.g., Parkinson's disease, Stroke with paralysis) that directly affect muscle mass and mobility; Prolonged use of systemic corticosteroids (which cause secondary sarcopenia).